8MM Respiratory Syncytial Virus Prophylaxis Market Drug Analysis Report: Prophylactic Options to Continue to Diversify Due to Strength of Late-Stage Pipeline - Forecast to 2030
20. Dezember 2024 10:05 ET
|
Research and Markets
Dublin, Dec. 20, 2024 (GLOBE NEWSWIRE) -- The "Respiratory Syncytial Virus Prophylaxis: Eight-Market Drug Forecast and Market Analysis - Update" report has been added to ResearchAndMarkets.com's...
Myositis Therapeutics Market Report 2024: Comprehensive Insights about 18+ Companies and 20+ Pipeline Drugs
18. Dezember 2024 09:37 ET
|
Research and Markets
Dublin, Dec. 18, 2024 (GLOBE NEWSWIRE) -- The "Myositis - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights...
Bio Usawa Names Former Ghana Food and Drug Authority Director Eric Karikari-Boateng as Head of Global Regulatory Strategy
17. Dezember 2024 10:15 ET
|
Bio Usawa Inc
Bio Usawa, Inc., a company committed to delivering affordable biotherapies in Africa, named Eric Karikari-Boateng its Head of Global Regulatory Strategy
FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Forecast to 2034 - Immunovant Advances FcRn Inhibitor Pipeline with Promising Results and FDA Green Light for Pivotal Trial
11. Dezember 2024 06:25 ET
|
Research and Markets
Dublin, Dec. 11, 2024 (GLOBE NEWSWIRE) -- The "FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's...
Chronic Pseudomonas Aeruginosa Pulmonary Infections Pipeline Insight 2024 - Pipeline Drug Profiles, Including Clinical and Non-clinical Stage Products
06. Dezember 2024 04:13 ET
|
Research and Markets
Dublin, Dec. 06, 2024 (GLOBE NEWSWIRE) -- The "Chronic Pseudomonas Aeruginosa Pulmonary Infections - Pipeline Insight, 2024" has been added to ResearchAndMarkets.com's offering.This report provides...
Immuno-Oncology Strategic Industry Research Report 2023-2024 & 2030: Approval of Pembrolizumab (Keytruda) and Nivolumab (Opdivo), which Target PD-1 and PD-L1 Pathways have Set New Benchmarks
05. Dezember 2024 10:16 ET
|
Research and Markets
Dublin, Dec. 05, 2024 (GLOBE NEWSWIRE) -- The "Immuno-Oncology - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Immuno-Oncology...
Combination Antibody Therapy Strategic Research Report 2024: Global Market Value to Reach $443 Billion by 2030 - Increased Use in Oncology Generates Demand for Multi-targeted Antibody Treatments
02. Dezember 2024 06:42 ET
|
Research and Markets
Dublin, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The "Combination Antibody Therapy - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for...
Peptide Cancer Drug Market Research 2024-2030: 230 Drugs in Clinical Trials, 30 Approved Drugs, $18 Billion Opportunity, Commercially Approved Peptide Cancer By Brand Name, Company and Indication
27. November 2024 04:10 ET
|
Research and Markets
Dublin, Nov. 27, 2024 (GLOBE NEWSWIRE) -- The "Peptide Cancer Drug Market Size, Dosage, Drug Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's...
Industrial Biomanufacturing Market Report 2025-2035, with Profiles of 1,100+ Companies Active in the Industrial Biomanufacturing Space
26. November 2024 07:30 ET
|
Research and Markets
Dublin, Nov. 26, 2024 (GLOBE NEWSWIRE) -- The "Global Market for Industrial Biomanufacturing 2025-2035" report has been added to ResearchAndMarkets.com's offering. This comprehensive market...
Monoclonal Antibody Collaboration and Licensing Analysis Report 2024 with Directory of 639 Deals Signed Since 2019 by Company A-Z, Deal Type and Therapeutic Target
26. November 2024 06:29 ET
|
Research and Markets
Dublin, Nov. 26, 2024 (GLOBE NEWSWIRE) -- The "Monoclonal Antibody Collaboration and Licensing Deals 2019-2024" report has been added to ResearchAndMarkets.com's offering. Fully revised and...